Individuals with atherosclerotic cardiovascular disease remain at high risk of recurrent events.
Some of this risk may be ascribed to practical factors such as clinical inertia or cross-country disparities in access to effective lipid lowering therapies, as highlighted by the EU-wide DA VINCI study.
Across 18 countries in the European Union, less than half of secondary prevention patients received high intensity statin therapy for managing low-density lipoprotein cholesterol (LDL-C), as recommended by clinical guidelines.
Inadequacies in guideline implementation are also common to other global regions. Additionally, strict reimbursement criteria or lack of funding limit access to newer treatments in some regions...
- The Initiative
- What's Residual Risk?
- R3I Videos & Slides
- R3I Events